(Total Views: 431)
Posted On: 12/22/2018 12:47:50 PM
Post# of 72447
Cash-poor Agenus finds itself a generous partner in Gilead
https://endpts.com/cash-poor-agenus-finds-its...res-surge/
$120M upfront + $30M equity + $1.7B in milestones on 5 pre-clinical assets.
This moved their market cap from ~$140M to $270M.
We should be able to get something like that with two small phase 2's completed on B-OM and IBD. Probably smaller milestones but open-ended royalties.
Shouldn't Kevetrin be able to fetch something like this as well? What the hell are we doing down here at $19M?
https://endpts.com/cash-poor-agenus-finds-its...res-surge/
$120M upfront + $30M equity + $1.7B in milestones on 5 pre-clinical assets.
This moved their market cap from ~$140M to $270M.
We should be able to get something like that with two small phase 2's completed on B-OM and IBD. Probably smaller milestones but open-ended royalties.
Shouldn't Kevetrin be able to fetch something like this as well? What the hell are we doing down here at $19M?
(3)
(0)
